Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Columbia Labs

This article was originally published in The Tan Sheet

Executive Summary

Class action suit filed in summer 2000 alleging company made "materially misleading statements and omissions" about its nonoxynol-9 spermicide-containing Advantage-S and Rx progesterone gel fertility treatment Crinone dismissed May 9. Class action pertained to stockholders purchasing Columbia shares between Nov. 8, 1999 and June 9, 2000. Advantage-S was found to be ineffective at protecting against HIV in a UNAIDS Phase III trial conducted last year (1"The Tan Sheet" July 17, 2000, p. 8)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS092536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel